Navigation Links
OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
Date:9/22/2010

terin levels occurred within the first cycle of custirsen treatment when compared to levels in the docetaxel arm, indicating on-target biological activity of custirsen; - Measurable stable disease was higher (77% in custirsen plus docetaxel arm versus 50% in docetaxel arm) and disease progression, without any response to therapy, was lower (4% in custirsen plus docetaxel arm versus 17% in docetaxel arm). The incidence of overall objective response was comparable; - Because the primary endpoint of the study was achieved and survival benefit was observed, custirsen warrants further study in Phase 3 trials.

"Despite the number of new treatment options for patients with advanced prostate cancer, many patients will eventually experience disease progression. We believe custirsen has the potential to reduce treatment resistance thereby increasing the efficacy of various therapeutic agents such as docetaxel, and are hopeful this will be confirmed through the Phase 3 development program," said Scott Cormack, president and CEO of OncoGenex.

In 2009, Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. entered into a global license and collaboration agreement to develop and commercialize custirsen.

Phase 2 Study Design

In this Phase 2 study, 82 patients were randomized to one of two treatment arms to receive either 640 mg per week of custirsen by intravenous infusion in combination with docetaxel/prednisone or docetaxel/prednisone alone. Patients in both treatment arms received therapy until disease progression, toxicity or completion of ten 3-week cycles of therapy. The primary endpoint of the trial was to achieve a 50% reduction in PSA from baseline in over 50% of the patients treated with custirsen plus docetaxel. Secondary endpoints included determining objective response and duration of response in those patients with measurable disease at baseline, determining the tolerability and toxicity of weekly custirsen in combinati
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Reports Second Quarter Financial Results
2. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
6. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
7. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
8. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
9. OncoGenex Reports Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015   ... Diagnostik und Therapie, Strahlendosismanagement und IT-Lösungen für die ... Royal Philips (NYSE: PHG, AEX: PHIA) gab ... (ECR) bekannt, der vom 4. bis 8. März in ... Ständen Nr. 102 and 110 wird ...
(Date:3/3/2015)... 2015 NASA astronaut Scott Kelly , who ... spend a year living and working on the International Space ... to 7 a.m. EDT Monday, March 9. Kelly ... completes the final weeks of his training. The interviews will ... Television highlighting his mission training and previous spaceflights. ...
(Date:3/3/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) has ... 2015 - 2025" report to their offering. ... an extensive study on the marketed and pipeline gene ... in this field for over a decade but there ... markets; one approved in the EU). There are many ...
(Date:3/3/2015)... March 3, 2015 Adaptive Biotechnologies announced today ... joining its Board of Director as Chair of the ... Zillow Group, Chad oversees all finance, treasury and accounting ... company,s core finance, treasury and accounting functions, and led ... acquisitions. In 2013, he was named Puget Sound Business ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... Northwestern University have nanoengineered a new kind of fiber ... a multidisciplinary team that includes groups from other universities ... Nancy J. Farley Professor in Manufacturing & Entrepreneurship at ... his group have created a high performance fiber from ...
... Inc. (Nasdaq: SQNM ) today announced that ... that priced on December 2, 2010 have exercised in ... of its common stock.  Including the additional shares being ... public offering price of $6.00 per share, resulting in ...
... have discovered a simple way to make carbon ... researcher Bruce Weisman, a pioneer in nanotube spectroscopy, ... batches of single-walled carbon nanotubes and exposing them ... atoms and systematically changes their near-infrared fluorescence. ...
Cached Biology Technology:Researchers create new high-performance fiber 2Researchers create new high-performance fiber 3Sequenom Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Sequenom Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Light touch brightens nanotubes 2Light touch brightens nanotubes 3
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... sham acupuncture treatments may help alleviate side effects of drugs ... CANCER , a peer-reviewed journal of the American Cancer ... patients. The results also raise the question of whether sham ... beneficial effects. Breast cancer patients who take a type ...
... 22, 2013Scientists at The Scripps Research Institute (TSRI) have ... the rapid selection of chemical compounds that have a ... compounds work. To illustrate the power of the ... a compound that shows promise for treating obesity-linked diabetes. ...
... A team of researchers studying plants has assembled the ... order in which flowering plants evolved specific strategies, such ... areas with cold winters. The researchers, including University of ... Dec. 22 in the journal Nature . ...
Cached Biology News:Breast cancer patients experience fewer side effects from anticancer drug when receiving acupuncture 2Innovative screening strategy swiftly uncovers new drug candidates, new biology 2Innovative screening strategy swiftly uncovers new drug candidates, new biology 3Innovative screening strategy swiftly uncovers new drug candidates, new biology 4Researchers create largest evolutionary 'timetree' of land plants to investigate traits that permit survival in cold climates 2Researchers create largest evolutionary 'timetree' of land plants to investigate traits that permit survival in cold climates 3
Acid phosphatase (Potato). Monospecific by IEP. Some cross reactivity between Acid phosphatases of other species may occur....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
... Yersinia pestis This antibody is ... Immunogen: Purified F1 ... vaccine strain EV76. Specificity: ... capsular antigen. There is no cross-reactivity ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: